Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AK112 with or without AK117 in metastatic colorectal cancer
CTR20221153Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Jul 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, ligufalimab in colorectal adenocarcinoma, metastatic colorectal adenocarcinoma (mCRC), sponsored by Akeso, Inc.. Started Jul 2022; status: active.
02
Drugs
ivonescimabligufalimab
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on CTR20221153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221153.